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Structured Summary  
 
Background 
Carbapenemase-producing Enterobacteriaceae (CPE) can cause healthcare–associated 
infections with high mortality rates.  New Delhi metallo-beta-lactamase-1 (NDM-1) is 
amongst the most recently discovered carbapenemases. 
Aim 
To report the first outbreak of NDM-1 CPE in Ireland, including microbiological and 
epidemiological characteristics, and assessing the impact of infection prevention and control 
measures. 
Methods 
Retrospective microbiological and epidemiological review. Cases were defined as patients 
with a CPE positive culture. Contacts were designated as roommates or ward mates.  
Findings 
This outbreak involved ten patients, with a median age of 71 years (range 45-90 years), 
located in three separate but affiliated healthcare facilities. One patient was infected (the 
index case); the nine others were colonised. Nine NDM-1-producing Klebsiella pneumoniae, 
a NDM-1-producing Escherichia coli and a K. pneumoniae carbapenemase (KPC)-producing 
Enterobacter cloacae were detected between week 24 2014 and week 37 2014. Pulsed field 
gel electrophoresis demonstrated similarity. NDM-1 positive isolates were meropenem 
resistant with MICs ranging from 12 to 32 µg/ml. All were tigecycline susceptible (MICs ≤1 
µg/ml). One isolate was colistin resistant (MIC 4.0 µg/ml; mcr-1 gene not detected). In 2015, 
four further NDM-1 isolates were detected.  
Conclusions  
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The successful management of this outbreak was achieved via the prompt implementation of 
enhanced infection prevention and control practices to prevent transmission. These patients 
did not have a history of travel outside of Ireland, but a number had frequent hospitalisations 
in Ireland, raising concerns regarding the possibility of increasing but unrecognised 
prevalence of NDM-1 and potential decline in value of travel history a marker of colonisation 
risk.  
 
 
Keywords 
Carbapenemase-producing Enterobacteriaceae, New Delhi metallo-beta-lactamase-1 (NDM-
1), multi-drug resistant organism, outbreak, Ireland.  
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Introduction 
 
Enterobacteriaceae are Gram-negative colonisers of the human gut. Carbapenemase-
producing Enterobacteriaceae (CPE) are resistant to most classes of antimicrobials 
1
. New 
Delhi metallo-beta-lactamase-1 (NDM-1) is amongst the most recently discovered 
carbapenemase enzymes. The responsible blaNDM-1 gene is thought to have originated in the 
environment from plant pathogens and is plasmid-borne 
2
. NDM-1 confers broad spectrum 
beta-lactam resistance mediated by hydrolysis of all β-lactam antimicrobials, with the 
exception of monobactams, such as aztreonam 
3
. Many NDM-1-producing bacteria remain 
susceptible only to colistin, fosfomycin and tigecycline 
4, 5
. Since first reported as implicated 
in human disease 
6
, NDM-1-producing bacteria have been recovered from numerous infection 
sites including device-associated infections, intra-abdominal, urinary tract, bloodstream and 
surgical wounds 
7
. Publications have described most variants of the enzyme as having 
originated in Asia 
8
.  
 
Acquisition of NDM-1-producers has been reported as associated with travel to known 
reservoirs areas, notably the Indian subcontinent (Pakistan, India, Sri Lanka) and the Balkan 
countries 
9-11
, where prevalence of community carriage is estimated to be 5-15% 
12
. Global 
dissemination is facilitated by intercontinental travel 
13
, including healthcare tourism 
14
, and 
migration 
15
. International spread has been rapid 
16
. The NDM isolates identified in Ireland 
prior to this outbreak were isolated or paired cases from a number of hospitals countrywide 
and generally with an identifiable link with travel. Dissemination of the blaNDM-1 gene, like 
other similar resistance mediators, is facilitated by inadequate infection prevention and 
control practice in healthcare settings 
17
, uncontrolled or poorly controlled antimicrobial use 
18
, inadequate practices related to food preparation 
19
, water treatment and general sanitation 
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13
. The largest reported NDM outbreak to date in a non-endemic country was reported from 
Poland in 2015, where 374 cases of infection or colonisation, with a variety of NDM-
producing Enterobactericeae, were identified from 40 hospitals over a two-year period 
20
. 
 
In this report, we describe what we believe to be the first outbreak of NDM-1-producing 
Enterobacteriaceae in Ireland, which occurred in 2014.   
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Methods 
Setting 
The Department of Clinical Microbiology at University Hospital Limerick (UHL) provides a 
centralised microbiology service for six acute hospital sites (800 beds; population circa 
380,000 people). As an aid to contextualising this outbreak, it is notable that 48 K. 
pneumoniae carbapenemase (KPC) and one imipenem-hydrolyzing beta-lactamase (IMI)-
producing isolates were detected at UHL between February 2009 and May 2015, as 
previously published 
21
.  
 
Study definitions 
Cases were defined as patients with a NDM-1 positive culture from any site during their 
hospitalisation. Contacts were designated as roommates or ward mates.  
 
Microbiological and molecular detection of NDM-1 
Since 2011, CPE surveillance at UHL had been performed on stool samples or rectal swabs 
using KPC-producer selective chromogenic agar (CHROMagar™ KPC, Paris, France). 
MALDI-TOF MS (Bruker Diagnostics) identification was performed on all colonies, as 
previously described 
22
. Antimicrobial susceptibility testing was performed using broth 
microdilution (ARIS Sensititre
®
 system-Thermo Fisher Scientific Inc, Masachusettts, USA).  
Elevated carbapenem minimum inhibitory concentrations (MICs) for meropenem and 
ertapenem were confirmed by E-test (AB Biodisk, Solna, Sweden) following the European 
Committee on Antimicrobial Susceptibility Testing (EUCAST) guidelines; ertapenem 
resistance MIC >1 g/l, meropenem resistance MIC >8 g/l. Isolates with elevated carbapenem 
MICs were further evaluated using the modified Hodge test (MHT). Commercially available 
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diagnostic kits (Rosco Diagnostica A/S, Taastrip, Denmark) consisting of meropenem discs 
supplemented with β-lactamase inhibitors: meropenem + dipicolinic acid; meropenem + 
boronic acid; and meropenem + cloxacillin were used to phenotypically distinguish CPE 
isolates. Isolates were referred to the National Carbapenemase-Producing Enterobacteriaceae 
(CPE) Reference Laboratory Service (CPERLS) at University Hospital Galway, Ireland for 
CPE confirmation by molecular methods. Genetic relationship of NDM-1 isolates was 
determined by pulsed field gel electrophoresis (PFGE).  
 
Details of NDM-1 positive patients 
A retrospective chart review assessing clinical and epidemiologic characteristics was 
completed for all patients involved including: dates of admission, transfers, and hospital 
discharges; locations within the hospital; procedures and operative notes; use of invasive 
devices; biochemical and haematological blood test results; antimicrobials received and 
documentation of a travel history.   
  
Infection control interventions  
The isolation of a NDM-1-producing K. pneumoniae triggered initiation of the hospital’s 
outbreak management protocol. Rectal swabs or stool samples were obtained from all 
contacts of the index case. Information leaflets were distributed to all patients and family as 
appropriate. The Public Health England CPE toolkit was implemented during the outbreak 
23
. 
All infected or colonised patients were barrier nursed utilising long-sleeved disposable gowns 
and gloves, and single rooms were used when available.  Chlorhexidine gluconate wash-
cloths were employed for bathing of patients. Dedicated equipment was prioritised for NDM-
positive inpatients, both infected and colonised, but was not available for all NDM-contacts. 
A semi-automated electronic data surveillance system, ICNet™ (Baxter), was used to collate 
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the records of the outbreak meetings and patients involved 
24
. All patients identified as CPE 
positive or as CPE contact were flagged on the ICNet™ system and their medical charts were 
assigned a CPE alert sticker, placed on the front cover.  
 
During the thirteen weeks over which this outbreak occurred, there were an additional 13 
KPCs and one oxacillin-hydrolyzing carbapenamase (OXA-48) identified. This was the first 
OXA isolated at UHL. At a practical level, staff were familiar with the term ‘KPC’, but the 
introduction of the term ‘NDM’ and ‘OXA’ created confusion and the concept of three 
different types of CPE circulating simultaneously generated alarm amongst clinical staff. 
Members of the infection prevention and control team provided additional education sessions 
at ward level to nursing staff and healthcare assistants. New CPE posters were designed 
explaining the different CPE types in simple and clear language, and these were placed in the 
doctors’ residence (communal living space) and on all wards. Anecdotal feedback received 
regarding the posters was positive. An electronic link to the location of the CPE guideline on 
the hospital intranet was disseminated on a memo to all staff. 
 
Hand hygiene audits were performed with greater frequency in affected areas, which 
involved twice weekly observational audits at ward level. Enhanced cleaning, twice daily, of 
all implicated clinical areas and patient equipment was instigated in parallel with increased 
auditing of cleaning practice. The index cases’ room in the ICU and all ward areas, where 
positive NDM-1 patients had been admitted, underwent routine cleaning followed by 
hydrogen peroxide vapour decontamination post-discharge. A deep clean of the emergency 
department (ED) including the waiting room and resuscitation areas was performed as seven 
patients involved in the outbreak had been admitted via the ED. High-touch surfaces such as 
door handles, bedside lockers and chairs and bed rails were emphasised by the hospital 
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hygiene nurse manager for cleaning to reduce cross-transmission. An ultraviolet torch was 
used to assess the quality of cleaning performed and face-to-face feedback regarding cleaning 
deficits was provided to cleaning operatives. Environmental sampling was not performed 
during this outbreak.   
 
A further initiative was introduced involving, on a daily basis, a joint pharmacist/clinical 
microbiologist handover of all in-house carbapenem prescriptions, and subsequent discussion 
by the either the microbiology consultant or registrar with clinical teams regarding alternative 
agents where appropriate.  
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Results 
 
Index Case  
The index case was a community-dwelling Irish female. In the summer of 2014, she was 
admitted with sepsis. Blood and peritoneal fluid cultures confirmed Escherichia coli. Initial 
admission was to a six-bed bay in a general medical ward preceding transfer the following 
day to a single room in the intensive care unit (ICU). Admission screens confirmed prior 
colonisation with meticillin-resistant Staphylococcus aureus (MRSA) and vancomycin-
resistant Enterococcus faecium (VRE). A rectal screen at that time did not detect CPE. 
Empiric therapy utilised intravenous (IV) ceftazidime 2g every 8 hours and gentamicin. As 
she did not respond to initial therapy, treatment was changed to meropenem 1g IV every 8 
hours, metronidazole 500mg IV TDS and vancomycin 1.5g IV every 12 hours but was de-
escalated to meropenem monotherapy.    
 
Seven days post admission, a rectal CPE screen (routine for ICU patients) detected a CTX-M  
extended spectrum beta-lactamase (ESBL)-producing K. pneumoniae and NDM-1-producing 
K. pneumoniae. A skin rash developed and diagnostic biopsies were performed on the left 
forearm. An abscess developed at the skin biopsy site and a CTX-M ESBL-producing K. 
pneumoniae and NDM-1-producing K. pneumoniae were isolated from the abscess discharge.  
IV tigecycline 50mg every 12 hours was initiated and the site was debrided surgically. The 
patient died 2 months following admission secondary to refractory soft tissue sepsis.  
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Microbiological 
Prior to this outbreak, a case of NDM-producing Enterobacteriaceae had not been identified 
in our laboratory. None of the patients in this outbreak were known to have prior colonisation 
with extended-spectrum beta-lactamase (ESBL) producers based on previous screening. 
Three patients had been screened for CPE before this outbreak but CPE was not detected on 
those occasions.  
 
In summary, nine NDM-1-producing K. pneumoniae, a NDM-1-producing Escherichia coli 
and a KPC-producing Enterobacter cloacae were detected. Of note, the NDM-1-producing 
Escherichia coli and a KPC-producing Enterobacter cloacae were identified in one patient. 
The isolates were detected in samples from UHL and two affiliated regional hospitals, located 
10km and 40km away, respectively.   
 
Clinical specimens that were positive for NDM-1-producing isolates included mid-stream 
urine samples (n=2), rectal swabs (n=8) and skin biopsy samples (n=3) from the index case.  
NDM-1-producing isolates were meropenem-resistant with MICs ranging from 12 to 32 
µg/ml. All isolates were tigecycline susceptible (MICs ≤1 µg/ml). One isolate was colistin-
resistant (MIC 4.0 µg/ml; mcr-1 gene negative). PFGE demonstrated that the isolates were 
closely related (Figure 1). Multilocus sequence typing (MLST) was not performed.  
 
The Outbreak: Patient demographics & epidemiological factors 
The patient demographics are summarised in Table 1. All were in full-time residence in 
Ireland. The screening policy in operation at the time of this outbreak, and currently, is that 
all patients are screened on admission if: admitted to the ICU or high dependency unit (HDU) 
at UHL; transferred from another hospital in Ireland; have had an acute admission in the past 
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12 months to any hospital within our hospital group (except for paediatric, maternity or 
orthopaedic); or if hospitalised abroad. Haemodialysis patients are screened every three 
months. Patients in ICU and HDU are screened weekly until discharge. During an outbreak, 
screening of all patients with epidemiological and environmental links to CPE positive 
patients, via rectal swab or stool specimen, is performed weekly. CPE screening is performed 
for a period of four weeks until no new cases of CPE colonisation or infection are detected.   
 
In June 2014, two contacts of the index case prior to her ICU admission were identified 
(Patients B, D). Both had been on the medical ward with the index case during her 24-hour 
admission prior to transfer to ICU. Patient B was screened, identified as NDM-1-producer 
positive and was isolated. Patient D was discharged prior to CPE screening. She re-presented 
for admission in July 2014 and was re-admitted to a 6-bedded area on the same medical ward 
as she had been admitted to previously in June 2014. She had a CPE screen performed and 
was confirmed as NDM-1-producer positive and she was isolated immediately. Patients E, F 
and H, all were ward contacts of the index case, were NDM-1-producer positive. Patients G 
and I were identified from routine admission rectal CPE screens performed during the 
outbreak period. Both had admissions to UHL in the prior 12 months; neither had contact 
with the index case.   
 
Two additional NDM-1-producer positive patients were identified during the outbreak period 
but their CPE positivity was not explained by any apparent epidemiologic link with other 
outbreak related cases. These were not contacts of the index case and had no contact with 
UHL during the defined outbreak period, including the outpatients and the emergency 
departments. Patient C was identified as CPE positive from a screening rectal swab that was 
performed at a regional hospital 10km from UHL. This CPE screen was performed as per 
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screening protocol because the patient had been admitted to UHL in the prior 12 months. His 
last admission to UHL was almost five months before the outbreak was declared. Patient J, 
identified as being CPE positive following a MSU sample sent for routine culture and 
sensitivity as the patient had symptoms of cystitis, was located in a regional hospital 40km 
away from UHL. Notably, this latter isolate was determined by PFGE (Figure 1) to be the 
isolate most distantly related to the other outbreak isolates. 
 
Given the identification of NDM-1 at three different associated hospitals, a decision was 
made to perform contact tracing and screening of all contacts at each site. As a result of that 
exercise, during the outbreak, 2204 CPE screens, including contact tracing and routine CPE 
screening, were processed in our laboratory, which in addition to detecting the NDM-1 
isolates, also identified 13 new KPCs and one OXA-48.  
 
Carbapenem consumption 
Only the index case had been prescribed meropenem during the current admission. This was 
prior to the isolation of a NDM-positive culture and, in total, the patient was administered 
five days of meropenem.  
 
NDM-1 isolates identified in 2015 
In week 31 2015, a NDM-1 producing K. pneumoniae was identified in an MSU sample from 
an 81-year-old female residing in a private LTCF. This patient was a contact of the index 
case during the outbreak but CPE was not detected at the time. PFGE demonstrated similarity 
to the 2014 isolates. In week 32 2015, a NDM-1-producing K. pneumoniae was identified 
from a rectal swab of a 71-year old public LTCF patient who was known to be previously 
colonised with a KPC-producing Citrobacter freundii. This isolate did not demonstrate 
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similarity to previous isolates. In week 42 2015, a NDM-1-producing K. pneumoniae was 
isolated by rectal swab from an admission CPE screen of a patient repatriated from Bosnia. 
She had not been admitted to UHL previously and had never had any specimens processed in 
the UHL microbiology laboratory. This isolate did not demonstrate PFGE similarity. In week 
48 2015, a NDM-1-producing E. coli was detected in a 60-year patient who had been recently 
hospitalised in India. Again this isolate did not demonstrate similarity. 
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Discussion 
 
The source of the index case patient’s NDM-1-producer acquisition remains uncertain 
although acquisition during the hospital admission of June 2014 is considered likely.  The 
index case had been on haemodialysis for 16 years and switched to peritoneal dialysis in 
2013 (five months prior to NDM-1 detection). In our care, all haemodialysis patients undergo 
surveillance CPE screening every three months, but the same screening is not conducted for 
peritoneal dialysis patients. The index case patient was screened for rectal CPE in December 
2013, at which time CPE was not detected. Following her transition to peritoneal dialysis, no 
further CPE screening was performed prior to her transfer to ICU on this final admission to 
UHL, at which time CPE was likewise undetected. She had never worked in a healthcare 
setting nor lived with any healthcare workers. She had no known travel to NDM-1 endemic 
areas.  
 
In this outbreak, international travel was not a recognised factor, implying that there may be a 
hospital and/or community burden of blaNDM-1 than had not been previously appreciated.  
Struelens et al.
 25
 reviewed 77 NDM-1 producing Enterobacteriaceae reported from 13 
European countries from 2008 to 2010. Among 55 of the cases with recorded travel history, 
31 had involved travel to, or admission to a hospital in, India or Pakistan, and five patients 
had been hospitalised in the Balkan region. Possible nosocomial acquisition accounted for 13 
of 77 cases (17%). In contrast, our outbreak more closely resembled the outbreak reported by 
Borgia et al. that occurred in Brampton, Ontario, Canada where five patients were identified 
as carrying NDM-1–producing K. pneumoniae; all of them epidemiologically linked with 
each other, but none with a relevant travel history 
26
. 
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NDM-1-producing K. pneumoniae and NDM-1-producing E. coli were identified from one 
hospital (UHL) and NDM-1 producing K. pneumoniae found in the two other affiliated 
hospitals. The dominant species in our NDM-1 outbreak was K. pneumoniae (Figure 1).  A 
successfully controlled outbreak in Mexico City reported the isolation of NDM-1 producing 
E. coli and NDM-1 producing E. cloacae from the same patient in addition to three NDM-1 
producing K. pneumoniae isolates derived from three other epidemiologically-related 
patients. In that outbreak, one plasmid (IncFII) was borne by all of the isolates 
27
. In a large 
outbreak reported from South Africa (as in our case, also from three acute hospitals), which 
persisted for 16 weeks in 2012, K. pneumoniae was also the dominant species and accounted 
for 28/38 isolates (74%) with E. cloacae accounting for the 5/38 (13%) 
28
.  
 
Learning from the outbreak 
In 2013, Lin et al. 
29
 reported substantial community reservoirs of CPE in the United States. 
Currently, there are no data available in Ireland regarding national prevalence of CPE in 
long-term care facilities (LTCF) as a national point prevalence study of LTCF relating to 
multidrug-resistant organisms has never been performed.  However, three of the ten patients 
in this outbreak were permanent residents of three separate LTCF (two public, one private) 
and one other patient was a permanent resident in a residential care facility for adults with 
learning disabilities (Table 1). Such a study is needed, justified by our data and the fact that, 
between 2009 and 2015, 140 CPE isolates were identified from clinical specimens of which 
12 CPE isolates originated in local public (n=10 isolates) and two private LTCF (n=2 
isolates) 
30
.    
 
Influenced by this outbreak, our antimicrobial stewardship has been modified. Overall 
hospital antibiotic consumption rate in defined daily doses (DDD) per 100 bed days used 
(BDU) demonstrates a reduction in carbapenem consumption. Between 2014 and the end of 
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2015, carbapenem consumption decreased by 21% (2014: 4.43 DDD/100BDU, 2015: 3.49 
DDD/100BDU). This compares very favourably with a 4% increase from 2013 (4.24 
DDD/100BDU) to 2014, 25% increase from 2012 (3.39 DDD/100BDU) to 2013, a 36% 
increase from 2011 (2.50 DDD/100BDU) to 2012 
30
.  
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Conclusions 
This outbreak and our other sporadic isolates indicate the changing epidemiology of NDM-1 
CPE. In Ireland, as elsewhere (e.g. Canada), absence of a history of travel to a known 
endemic area is of decreasing value in differentiating between those at risk of and those not at 
risk of colonisation or infection with NDM-1 producers. As the successful management of 
this outbreak demonstrates, prompt infection prevention and control practices are essential to 
prevent transmission. No staff or environmental screening was performed but extensive 
resources directed towards education, hand hygiene compliance, environmental disinfection, 
cleaning standards and reducing carbapenem consumption were successful in controlling 
rapid in-hospital transmission of NDM-1 producers. The subsequent detection of additional 
cases, in particular the related isolate from a nursing home resident in week 31 2015, 
demonstrates the difficulty of definitely eradicating these organisms once established in the 
“revolving door” systems of nursing homes and hospitals.   
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Table  
Table 1: Clinical characteristics of patients involved in the outbreak 
 
*LTCF: long term care facility 
Pt Age M/F 
Place of 
residence 
Date 
admitted 
 
Admitting 
diagnosis 
 
Treated with 
meropenem 
during 
admission 
Specimen 
Organism(s) 
isolated 
Carbapene
mase 
enzyme(s) 
detected 
Date of 
culture 
Infected/ 
Colonised 
Outcome 
Previous 
admission 
to 
hospital 
in 
prior 12 
months 
A 44 F Community 
Week 24 
(2014) 
Peritonitis  Yes Rectal swab 
Klebsiella 
pneumoniae 
NDM-1 
Week 
25 
(2014) 
Infected Died  Yes 
B 78 F Community 
Week 24 
(2014) 
Streptococcus 
milleri 
bacteraemia 
No 
Mid-stream 
urine 
Klebsiella 
pneumoniae 
NDM-1 
Week 
25 
(2014) 
Colonised 
Discharged to a 
LTCF* 
Yes 
C 61 M Community 
Week 25 
(2014) 
Urinary 
retention 
No Rectal swab 
Klebsiella 
pneumoniae 
NDM-1 
Week 
25 
(2014) 
Colonised 
Discharged to 
the community 
Yes 
D 65 F 
Residential 
care facility 
Week 30 
(2014) 
Urinary 
infection 
No Rectal swab 
Klebsiella 
pneumoniae 
NDM-1 
Week 
32  
(2014) 
Colonised 
Discharged to 
residential care 
Yes 
E 81 F 
Public 
LTCF 
Week 30 
(2014) 
Respiratory 
infection 
No Rectal swab 
Klebsiella 
pneumoniae 
NDM-1 
Week 
32  
(2014) 
Colonised 
Discharged to a 
LTCF 
Yes 
F 71 F Community 
Week 30 
(2014) 
Collapse No Rectal swab 
Klebsiella 
pneumoniae 
NDM-1 
Week 
32  
(2014) 
Colonised 
Discharged to a 
LTCF 
Yes 
G 89 F 
Private 
LTCF 
Week 32 
(2014) 
Congestive 
cardiac failure 
No Rectal swab 
Escherichia 
coli, 
Enterobacter 
cloacae 
NDM-1, 
KPC 
Week 
33 
(2014) 
Colonised 
Discharged to a 
LTCF 
Yes 
H 90 F Community 
Week 30 
(2014) 
Respiratory 
infection  
No Rectal swab 
Klebsiella 
pneumoniae 
NDM-1 
Week 
33  
(2014) 
Colonised Died  No 
I 75 M 
Public 
LTCF 
Week 35 
(2014 
Respiratory 
infection 
No Rectal swab 
Klebsiella 
pneumoniae 
NDM-1 
Week 
35 
(2014) 
Colonised 
Discharged to a 
LTCF 
No 
J 53 F Community 
Week 37 
(2014) 
Skin and soft 
tissue infection 
No 
Mid-stream 
urine 
Klebsiella 
pneumoniae 
NDM-1 
Week 
37 
(2014) 
Colonised 
Discharged to 
the community 
No 
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Figure 1: Pulsed field gel electrophoresis of 12 K. pneumoniae isolates. ME 140282 is 
the index case.  
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Figure 2: Pulsed field gel electrophoresis of the two NDM-1 E. coli isolates.  
 
 
 
  
21 
 
Acknowledgements 
We thank the staff of the Microbiology Laboratory at UHL for their expertise in 
successfully dealing with this outbreak, Elaine McGrath for performing PFGE at 
University Hospital Galway and Sandra Guilfoyle, medical secretary at the UHL 
Department of Clinical Microbiology, for assisting with review of medical charts. 
 
Funding 
This study was funded in part by an Irish Society of Clinical 
Microbiologists research bursary, which is supported by Pfizer Ireland. 
 
Transparency declaration 
None to declare. 
 
Author contribution 
All authors made a substantial contribution to the acquisition and 
interpretation of data. CD performed final drafting of the manuscript.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
References  
 
  
22 
 
1. Gupta N, Limbago BM, Patel JB, Kallen, A.J. Carbapenem-resistant 
Enterobacteriaceae: epidemiology and prevention. Clin Infect Dis 2011; 53: 
60–67. 
 
2.  Sekizuka T, Matsui M, Yamane K et al.  Complete sequencing of the 
bla(NDM-1)-positive IncA/C plasmid from Escherichia coli ST38 isolate 
suggests a possible origin from plant pathogens. PLoS One 2011; 6: e25334. 
 
3.  Cornaglia G, Giamarellou H, Rossolini GM. Metallo-β-lactamases: a last 
frontier for β-lactams? Lancet Infect Dis 2011; 11: 381-93. 
 
4.  Livermore DM. Has the era of untreatable infections arrived? J Antimicrob 
Chemother. 2009; 64: i29-i36.  
 
5.  Nordmann P, Poirel L, Walsh TR, Livermore DM.  The emerging NDM 
carbapenemases. Trends Microbiol 2011; 19:588-95.  
 
6.  Yong D, Toleman MA, Giske CG et al.  Characterization of a new metallo-
beta-lactamase gene, bla (NDM-1), and a novel erythromycin esterase gene 
carried on a unique genetic structure in Klebsiella pneumoniae sequence type 
14 from India. Antimicrob Agents Chemother 2009; 53: 5046-54. 
7.  Wilson ME, Chen LH. NDM-1 and the role of travel in its dissemination. Curr 
Infect Dis Rep 2012; 14: 213-26.  
8.  Tada T, Miyoshi-Akiyama T, Dahal RK et al. NDM-8 metallo-β-lactamase in 
a multidrug-resistant Escherichia coli strain isolated in Nepal. Antimicrob 
Agents Chemother  2013; 57: 2394-6.  
9.  Mulvey MR, Grant JM, Plewes K, Roscoe D, Boyd, DA. New Delhi 
metallo-β-lactamase in Klebsiella pneumoniae and Escherichia coli, Canada. 
Emerg Infect Dis 2011; 17: 103-6. 
 
10.  Peirano G, Ahmed-Bentley J, Woodford N, Pitout JD. New Delhi metallo-
beta-lactamase from traveller returning to Canada. Emerg Infect Dis 2011; 17: 
242-4. 
11.  Tijet N, Alexander DC, Richardson D et al.  New Delhi metallo-beta-
lactamase, Ontario, Canada. Emerg Infect Dis 2011;17:306-7. 
12.  Perry JD, Naqvi SH, Mirza IA et al. Prevalence of faecal carriage of 
Enterobacteriaceae with NDM-1 carbapenemase at military hospitals in 
Pakistan, and evaluation of two chromogenic media. J Antimicrob Chemother 
2011; 66: 2288-94. 
13.  Walsh TR, Toleman MA. The new medical challenge: why NDM-1? Why 
Indian? Expert Rev Anti Infect Ther 2011; 9: 137-41.  
14.   Reed CM. Medical tourism. Med Clin North Am 2008; 92: 1433-46. 
 
15.  Nordmann P, Poirel L, Toleman MA et al. Does broad-spectrum beta-lactam 
resistance due to NDM-1 herald the end of the antibiotic era for treatment of 
  
23 
 
infections caused by Gram-negative bacteria? J Antimicrob Chemother 2011; 
66: 689-92. 
 
16.  Molton JS, Tambyah PA, Ang BS et al. The global spread of healthcare-
associated multidrug-resistant bacteria: A perspective from Asia. Clin Infect 
Dis 2013; 56: 1310-8.  
 
17.  Johnson AP, Woodford N. Global spread of antibiotic resistance: the example 
of New Delhi metallo-β-lactamase (NDM)-mediated carbapenem resistance. J 
Med Microbiol. 2013; 62: 499-513.  
 
18.  Walsh TR, Toleman MA. The emergence of pan-resistant Gram-negative 
pathogens merits a rapid global political response. J Antimicrob Chemother 
2012; 67: 1-3. 
 
19.  Walsh TR. New Delhi metallo-β-lactamase-1: detection and prevention. 
CMAJ. 2011; 183:1240-1. 
 
20.  Baraniak A, Izdebski R, Fiett J et al. NDM-producing Enterobacteriaceae in 
Poland, 2012-14: inter-regional outbreak of Klebsiella pneumoniae ST11 and 
sporadic cases. J Antimicrob Chemother 2016; 71: 85-91. 
 
21.  O'Connell, N.H., Power, L., O'Gorman, A, et al. Against the onslaught of 
endemic carbapenemase-producing Klebsiella pneumoniae, the war is being 
lost on the Irish Front. J Hosp Infect 2014; 87: 247-8. 
  
22.  O'Connor C, Fitzgibbon M, Powell J et al. A commentary on the role of 
molecular technology and automation in clinical diagnostics. Bioengineered 
2014; 5: 155-60. 
 
23.  Public Health England. Acute trust toolkit for the early detection, management 
and control of carbapenemase-producing Enterobacteriaceae Date of access: 
10/10/2015. 
http://www.hpa.org.uk/webw/HPAweb&HPAwebStandard/HPAweb_C/13171
40378529/ 
 
24.  http://www.icnetplc.com/en-gb. Date of access: 17.10.2015 
 
25.  Struelens MJ, Monnet DL, Magiorakos AP et al. New Delhi metallo-beta-
lactamase 1–producing Enterobacteriaceae: emergence and response in 
Europe. Euro Surveill 2010; 15: pii=19716.  
26.  Boria S, Lastovetska O, Richardson D et al. Outbreak of carbapenem-resistant 
enterobacteriaceae containing blaNDM-1, Ontario, Canada. Clin Infect Dis 
2012; 55: e109-17.  
27.  Torres-González P, Bobadilla-Del Valle M, Tovar-Calderón E et al. Outbreak 
caused by Enterobacteriaceae harboring NDM-1 metallo-β-lactamase carried 
in an IncFII plasmid in a tertiary care hospital in Mexico city. Antimicrob 
Agents Chemother 2015; 59: 7080-3. 
 
  
24 
 
28.  de Jager P, Chirwa T, Naidoo S, Perovic O, Thomas, J. Nosocomial Outbreak 
of New Delhi metallo-β-lactamase-1-producing Gram-negative bacteria in 
South Africa: A case-control study. PLoS One 2015; 10: e0123337.  
 
29.  Lin MY, Lyles-Banks RD, Lolans K et al. The importance of long-term acute 
care hospitals in the regional epidemiology of Klebsiella pneumoniae 
carbapenemase-producing Enterobacteriaceae. Clin Infect Dis 2013; 57: 1246-
52. 
 
30.  O’Connor C, O’Connell NH, Commane M et al. Limerick: forever associated 
with five lines of rhyme or infamous for irrepressible carbapenemase-
producing Enterobacteriaceae for all time? J Hosp Infect 2016; 93:155-156.   
 
 
. 
 
 
